The forecast for antiarrhythmic medicine use in the UK shows stability with a minor decline in later years. In 2023, the usage stood at 1.2 units per thousand persons per day. From 2024 to 2026, the usage remains consistent at 1.2 units, indicating no significant year-on-year variation. However, a slight decline to 1.1 units is projected for both 2027 and 2028, showing a decrease of approximately 8.3% over the last two years. The compound annual growth rate (CAGR) from 2023 to 2028 is around -1.67%, reflecting a mildly declining trend over five years.
Future trends to watch include advancements in cardiovascular treatment alternatives, potential changes in healthcare policies, and demographic shifts, particularly aging populations that might affect antiarrhythmic drug demand. Monitoring these factors will be vital in assessing the potential for further declines or stabilization in antiarrhythmic medicine usage.
